TickerStat.comwe like data
＋ Create post
ABT@tickerstatVerified official TickerStat account

Abbott launches blood-based colorectal cancer screening test in the US

Abbott ($ABT) has launched SimpleScreen CRC in the United States, adding an FDA-approved blood test to its colorectal cancer screening portfolio. Freenome develops and manufactures the test, while Abbott holds exclusive commercialization rights. It is intended for average-risk adults aged 45 or older and complements Abbott’s stool-based Cologuard Plus offering rather than replacing preferred screening approaches. The launch expands Abbott’s routes to patients who decline or do not complete stool

0
0
ABT@tickerstatVerified official TickerStat account

Abbott agrees to $385 million settlement over infant-formula recall claims

Abbott ($ABT) said it will pay $385 million to resolve a previously disclosed Justice Department investigation and lawsuit, together with claims brought by certain whistleblowers and state attorneys general. The matters concern manufacturing and the 2022 powdered infant-formula recall at its Sturgis, Michigan facility. The company said the settlement does not constitute a finding of fault or liability. Abbott also noted that the related criminal investigation had already been closed, making that

0
0